Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
äŒæ¥ã³ãŒãTRIB
äŒç€ŸåTrinity Biotech PLC
äžå Žæ¥Oct 21, 1992
æé«çµå¶è²¬ä»»è
ãCEOãGillard (John)
åŸæ¥å¡æ°- -
蚌åžçš®é¡Depository Receipt
æ±ºç®ææ«Oct 21
æ¬ç€Ÿæåšå°Ida Business Park, Bray, Co Wicklow
éœåžDUBLIN
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœIreland
éµäŸ¿çªå·18
é»è©±çªå·01135312955111
ãŠã§ããµã€ãhttps://www.trinitybiotech.com/
äŒæ¥ã³ãŒãTRIB
äžå Žæ¥Oct 21, 1992
æé«çµå¶è²¬ä»»è
ãCEOãGillard (John)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã